These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 29475063)

  • 1. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.
    Hu X; Xiao Y; Yu C; Zuo Y; Yang W; Wang X; Gu B; Li J
    Eur J Pharmacol; 2018 Apr; 825():85-91. PubMed ID: 29475063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-clinical pharmacodynamic study of a novel oral factor Xa inhibitor zifaxaban.
    Qiu X; Wang W; Zhao Z; Sun S; Tang L
    Eur J Pharmacol; 2018 Oct; 836():50-56. PubMed ID: 30125563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles.
    Furugohri T; Isobe K; Honda Y; Kamisato-Matsumoto C; Sugiyama N; Nagahara T; Morishima Y; Shibano T
    J Thromb Haemost; 2008 Sep; 6(9):1542-9. PubMed ID: 18624979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
    Honda Y; Kamisato C; Morishima Y
    Thromb Res; 2016 May; 141():17-21. PubMed ID: 26962981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological characterization of a novel factor Xa inhibitor, FXV673.
    Chu V; Brown K; Colussi D; Gao J; Bostwick J; Kasiewski C; Bentley R; Morgan S; Guertin K; Pauls HW; Gong Y; Zulli A; Perrone MH; Dunwiddie CT; Leadley RJ
    Thromb Res; 2001 Aug; 103(4):309-24. PubMed ID: 11562341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
    Kawamura M; Konishi N; Hiroe K; Shofuda K; Imaeda Y; Fujimoto T; Kubo K
    J Cardiovasc Pharmacol; 2010 Aug; 56(2):156-61. PubMed ID: 20410831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.
    Perzborn E; Strassburger J; Wilmen A; Pohlmann J; Roehrig S; Schlemmer KH; Straub A
    J Thromb Haemost; 2005 Mar; 3(3):514-21. PubMed ID: 15748242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of glycyrrhetinic acid as an orally active, direct inhibitor of blood coagulation factor xa.
    Jiang L; Wang Q; Shen S; Xiao T; Li Y
    Thromb Res; 2014 Mar; 133(3):501-6. PubMed ID: 24412029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amblyomin-X having a Kunitz-type homologous domain, is a noncompetitive inhibitor of FXa and induces anticoagulation in vitro and in vivo.
    Branco VG; Iqbal A; Alvarez-Flores MP; Sciani JM; de Andrade SA; Iwai LK; Serrano SM; Chudzinski-Tavassi AM
    Biochim Biophys Acta; 2016 Oct; 1864(10):1428-35. PubMed ID: 27479486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innovative Three-Step Microwave-Promoted Synthesis of
    Santana-Romo F; Lagos CF; Duarte Y; Castillo F; Moglie Y; Maestro MA; Charbe N; Zacconi FC
    Molecules; 2020 Jan; 25(3):. PubMed ID: 31979319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
    Morishima Y; Honda Y; Kamisato C; Shibano T
    Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
    Konishi N; Hiroe K; Kawamura M
    Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor.
    Abboud MA; Needle SJ; Burns-Kurtis CL; Valocik RE; Koster PF; Amour AJ; Chan C; Brown D; Chaudry L; Zhou P; Patikis A; Patel C; Pateman AJ; Young RJ; Watson NS; Toomey JR
    J Cardiovasc Pharmacol; 2008 Jul; 52(1):66-71. PubMed ID: 18645410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor.
    Chi L; Peng YW; Gibson G; Hicks G; Mertz TE; Rapundalo S; Janiczek N; Edmunds JJ; Leadley R
    J Cardiovasc Pharmacol; 2004 Oct; 44(4):493-500. PubMed ID: 15454859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor.
    Iwatsuki Y; Sato T; Moritani Y; Shigenaga T; Suzuki M; Kawasaki T; Funatsu T; Kaku S
    Eur J Pharmacol; 2011 Dec; 673(1-3):49-55. PubMed ID: 22040919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of ex vivo pharmacodynamic markers during inhibition of thrombosis by CI-1031 (ZK-807834), a novel direct factor Xa inhibitor.
    Chi L; Pen YW; Potoczak R; Gibson G; Hicks G; Mertz TE; Janiczek N; Juneau PL; Gallagher K; Leadley R
    Pharmacology; 2002 Feb; 64(2):76-83. PubMed ID: 11803247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and Thrombin, Factor Xa and U46619 Inhibitory Effects of Non-Amidino and Amidino N²-Thiophenecarbonyl- and N²-Tosylanthranilamides.
    Lee SH; Lee W; Nguyen T; Um IS; Bae JS; Ma E
    Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28561744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lufaxin, a novel factor Xa inhibitor from the salivary gland of the sand fly Lutzomyia longipalpis blocks protease-activated receptor 2 activation and inhibits inflammation and thrombosis in vivo.
    Collin N; Assumpção TC; Mizurini DM; Gilmore DC; Dutra-Oliveira A; Kotsyfakis M; Sá-Nunes A; Teixeira C; Ribeiro JM; Monteiro RQ; Valenzuela JG; Francischetti IM
    Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2185-98. PubMed ID: 22796577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of novel 2,3-dihydroquinazolin- 4(1H)-one derivatives as potential fXa inhibitors.
    Xing J; Yang L; Yang Y; Zhao L; Wei Q; Zhang J; Zhou J; Zhang H
    Eur J Med Chem; 2017 Jan; 125():411-422. PubMed ID: 27689724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Direct Factor Xa Inhibitory Peptide with Anti-Platelet Aggregation Activity from Agkistrodon acutus Venom Hydrolysates.
    Chen M; Ye X; Ming X; Chen Y; Wang Y; Su X; Su W; Kong Y
    Sci Rep; 2015 Jun; 5():10846. PubMed ID: 26035670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.